Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health Inc (NY: HIMS )

22.20 +1.56 (+7.56%)
Streaming Delayed Price Updated: 12:47 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health Inc

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Missed Out on Eli Lilly? Buy This Amazing Growth Stock Instead
The company expects to enjoy many GLP-1 tailwinds in 2025. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With Hims & Hers Health Stock Tuesday?
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Tuesday after the company reported strong third-quarter results and raised its full-year revenue outlook. Here's what you need to know. 
Via Benzinga
Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Decoding Hims & Hers Health's Options Activity: What's the Big Picture?
Via Benzinga
Smart Money Is Betting Big In HIMS Options
Via Benzinga
A Look Into Hims & Hers Health Inc's Price Over Earnings
Via Benzinga
Palantir, Trump Media, Hims & Hers Health, NXP Semiconductors, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow Jones Industrial Average fell 0.6% to 41,794.60. 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the report. 
Via Benzinga
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Hims stock jumped late Monday after the online pharmacy beat expectations. 
Via Investor's Business Daily
What's Going On With Hims & Hers Health Stock Monday?
Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million,... 
Via Benzinga
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's... 
Via Benzinga
Exposures Product Safety
How Is The Market Feeling About Hims & Hers Health?
Via Benzinga
This Is What Whales Are Betting On Hims & Hers Health
Via Benzinga
Decoding 6 Analyst Evaluations For Hims & Hers Health
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Could This Magnificent Pharma Stock 10x in the Next 5 Years?
Disrupting pharmacies is just the start for Hims & Hers. 
Via The Motley Fool
Hims & Hers Stock Dropped: Here's What You Need to Know
The GLP-1 drama continues at Hims & Hers. 
Via The Motley Fool
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health
Via Benzinga
What Is Going On With Hims & Hers Stock?
Big GLP-1 news could have an impact. 
Via The Motley Fool
Why Hims & Hers' Incredible Growth Will Continue
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is. 
Via The Motley Fool
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
Exposures Product Safety
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own... 
Via Benzinga
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
An industry group sued the FDA, claiming tirzepatide remains in shortage. 
Via Investor's Business Daily
Topics Lawsuit
Exposures Financial Legal Product Safety
Where Does Hims & Hers Stock Go From Here?
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? 
Via The Motley Fool
Exposures Product Safety
2 Incredibly Cheap Growth Stocks to Buy Right Now
Look beyond the stock price at the business when shares are volatile. 
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
Consistently investing even moderate sums can grow your portfolio with time. 
Via The Motley Fool
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.